SynthesisPeerJ2026
Serum total testosterone and the prognosis of patients with advanced liver disease: a systemic review and meta-analysis.
Synthesis in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advanced liver disease (ALD) is associated with significant morbidity and mortality worldwide. Emerging evidence suggests that sex hormonal imbalances, particularly low serum total testosterone (TT) levels, may influence the prognosis of patients with ALD. This meta-analysis aimed to evaluate the association between serum TT levels and the prognosis of patients with ALD. Methods: Comprehensive searches of PubMed, Embase, and Web of Science were performed from the inception of the searched databases up to November 13, 2025, to identify observational studies assessing the association between serum TT levels and the risk of all-cause mortality or liver transplant (LT) among patients with ALD. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model to account for the potential influence of heterogeneity. This systematic review was registered in PROSPERO (CRD42024578870). Results: Eight cohort studies encompassing 1,989 patients were included in the analysis. Findings demonstrated that low serum TT levels were significantly associated with an increased risk of all-cause mortality or LT during follow-up (RR: 1.87, 95% CI [1.57-2.23], Conclusion: Lower serum TT levels are significantly associated with a higher risk of all-cause death or LT in patients with ALD, indicating their potential utility as prognostic biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.